MAP3K4 — Mitogen-Activated Protein Kinase Kinase Kinase 4

MAP3K4 — Mitogen-Activated Protein Kinase Kinase Kinase 4[@wang2018]

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MAP3K4 — Mitogen-Activated Protein Kinase Kinase Kinase 4</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>MAP3K4</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>6q26</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>4216</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>602505</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000070731</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>Q9Y1R4</td>
</tr>
<tr>
<td class="label">Transcript Length</td>
<td>~4.5 kb coding sequence</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>1,721 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~190 kDa</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>High</td>
</tr>
<tr>
<td class="label">Testis</td>
<td>High</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>

MAP3K4 — Mitogen-Activated Protein Kinase Kinase Kinase 4[@wang2018]

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MAP3K4 — Mitogen-Activated Protein Kinase Kinase Kinase 4</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>MAP3K4</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>6q26</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>4216</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>602505</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000070731</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>Q9Y1R4</td>
</tr>
<tr>
<td class="label">Transcript Length</td>
<td>~4.5 kb coding sequence</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>1,721 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~190 kDa</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>High</td>
</tr>
<tr>
<td class="label">Testis</td>
<td>High</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">MAP2K4</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">MAP2K7</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">MAP2K3</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">MAP2K6</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">JNK1/2/3</td>
<td>Downstream target</td>
</tr>
<tr>
<td class="label">p38α/β</td>
<td>Downstream target</td>
</tr>
<tr>
<td class="label">TAK1</td>
<td>Upstream activator</td>
</tr>
<tr>
<td class="label">MLK3</td>
<td>Parallel pathway</td>
</tr>
<tr>
<td class="label">TAB1</td>
<td>Regulatory</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">NF-κB</td>
<td>Parallel activation</td>
</tr>
<tr>
<td class="label">PI3K/Akt</td>
<td>Negative regulation</td>
</tr>
<tr>
<td class="label">ERK/MAPK</td>
<td>Limited cross-talk</td>
</tr>
<tr>
<td class="label">TGF-β</td>
<td>Smad-independent</td>
</tr>
<tr>
<td class="label">Wnt/β-catenin</td>
<td>Developmental regulation</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/neurodegeneration" style="color:#ef9a9a">Neurodegeneration</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">36 edges</a></td>
</tr>
</table>

MAP3K4 (Mitogen-Activated Protein Kinase Kinase Kinase 4), also known as MEKK4, is a critical upstream regulator of stress-activated protein kinase signaling pathways. Located on chromosome 6q26, this gene encodes a serine/threonine protein kinase that plays essential roles in cellular stress responses, inflammation, and neuronal survival[^wang2018].

As a member of the MAP3K family, MAP3K4 sits at a crucial signaling node that integrates diverse extracellular and intracellular stress signals to activate downstream MAPK cascades, particularly the JNK (c-Jun N-terminal kinase) and p38 pathways.[@map3k4_stress] These pathways are profoundly [@map3k4_stress]implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis[^map3k4_stress].

Gene and Protein Structure

Gene Organization

Domain Architecture

MAP3K4 contains several distinct structural domains[^mekk4_structure]:

The kinase domain shares highest homology with other MAP3K family members (MEKK1-3), while the C-terminal region provides unique regulatory properties specific to MAP3K4.

Post-translational Modifications

MAP3K4 activity is tightly regulated by:

• Phosphorylation: Auto-phosphorylation and activation by upstream kinases
• Sumoylation: Negative regulation of kinase activity
• Ubiquitination: Proteasomal degradation
• Subcellular localization: Cytoplasmic vs. nuclear partitioning

Signaling Pathways

Downstream Targets

MAP3K4 activates multiple downstream MAPK pathways[^map3k4_jnk][^map3k4_p38]:

Pathway 1: JNK Cascade

• MAP3K4 -> MAP2K4/MAP2K7 -> JNK1/2/3 -> c-Jun, JunD, ATF2
• Functions: Apoptosis, inflammation, synaptic plasticity

• MAP3K4 -> MAP2K3/MAP2K6 -> p38alpha/beta/gamma/delta -> MAPKAPK2/3, ATF6
• Functions: Cytokine production, cell cycle, differentiation

Upstream Activators

MAP3K4 is activated by diverse stimuli:

• Cellular stress: UV radiation, oxidative stress, DNA damage
• Pro-inflammatory cytokines: TNF-α, IL-1β, IFN-γ
• Growth factors: EGF, BDNF
• G protein-coupled receptors: GPCR agonists
• Mitochondrial dysfunction: Energy stress, ROS

Expression Patterns

Tissue Distribution

MAP3K4 is widely expressed with highest levels in brain and testis:

Brain Expression

Within the central nervous system[^map3k4_development]:

• Neurons: High expression in pyramidal neurons (cortex, hippocampus)
• Astrocytes: Moderate expression; increases with activation
• Microglia: Inducible expression in response to injury
• Oligodendrocytes: Lower baseline expression

• Hippocampus: CA1-CA3 pyramidal cells, dentate granule cells
• Cerebral cortex: Layer 2-6 pyramidal neurons
• Cerebellum: Purkinje cells, granule cells
• Substantia nigra: Dopaminergic neurons
• Spinal cord: Motor neurons

Role in Neurodegeneration

Alzheimer's Disease

MAP3K4 contributes to Alzheimer's disease pathogenesis through multiple mechanisms[^map3k4_ad][^map3k4_tau]:

1. MAPK Signaling Dysregulation

• Chronic activation of JNK and p38 pathways in AD brain
• Correlation with neurofibrillary tangle burden
• Mediation of tau hyperphosphorylation through direct and indirect effects on GSK-3β

• MAP3K4 activated by Aβ exposure in neurons
• Contributes to synaptic dysfunction and dendritic spine loss
• Mediates Aβ-induced inflammatory responses

• MAP3K4 in microglial activation and cytokine production
• Amplifies chronic neuroinflammation in AD
• Potential link between Aβ deposition and microglial response

• JNK-mediated AMPA receptor internalization
• Impairment of LTP and synaptic plasticity
• Contribution to cognitive decline[^map3k4_synapse]

• Stress-induced MAP3K4 activation affects mitochondrial quality control
• May exacerbate energy failure in AD neurons[^map3k4_mito]

Parkinson's Disease

In Parkinson's disease, MAP3K4 plays complex roles in dopaminergic neuron survival[^map3k4_pd]:

1. Dopaminergic Neuron Vulnerability

• High basal MAP3K4 expression in substantia nigra neurons
• Sensitive to oxidative stress and mitochondrial toxins
• JNK-mediated apoptosis pathway activation

• MAP3K4 activated by α-synuclein aggregates
• Contributes to progressive neurodegeneration
• Potential amplification loop of protein stress and kinase activation

• 1-Methyl-4-phenylpyridinium (MPP+) activates MAP3K4
• Links mitochondrial dysfunction to JNK activation
• Relevance to idiopathic PD pathogenesis

• MAP3K4 in microglial activation by α-synuclein
• Production of pro-inflammatory cytokines (TNF-α, IL-1β)
• Possible propagation of neuroinflammation

Amyotrophic Lateral Sclerosis

MAP3K4 involvement in ALS[^map3k4_als]:

• Rare mutations identified in familial ALS cases
• Motor neurons particularly vulnerable to JNK-mediated apoptosis
• Activated by mutant SOD1, TDP-43, and FUS protein aggregates
• Contributes to excitotoxicity through glutamate signaling

Other Neurodegenerative Conditions

• Huntington's Disease: MAP3K4 activated by mutant huntingtin
• Multiple Sclerosis: Regulates demyelination and oligodendrocyte death
• Frontotemporal Dementia: TDP-43 pathology links to MAP3K4 signaling

Cellular Functions

Stress Response

MAP3K4 serves as a central integrator of cellular stress signals[^map3k4_stress]:

• Oxidative stress: Activated by ROS through direct and indirect mechanisms
• ER stress: Integrated unfolded protein response signaling
• DNA damage: ATM/ATR-dependent activation
• Heat shock: Activation by cellular stress response

Apoptosis Regulation

The role of MAP3K4 in apoptosis is context-dependent[^map3k4_apoptosis]:

• Pro-apoptotic: JNK activation leads to BIM expression and mitochondrial apoptosis
• Anti-apoptotic: Can activate survival pathways under certain conditions
• Neuronal context: Generally promotes death in stressed neurons

Neuroinflammation

MAP3K4 critically regulates neuroinflammatory responses[^map3k4_inflammation]:

• Microglial activation and cytokine production
• T cell recruitment and CNS inflammation
• Blood-brain barrier integrity
• Cross-talk with NF-κB pathway

Development and Plasticity

Beyond disease, MAP3K4 plays roles in[^map3k4_development]:

• Neuronal differentiation during development
• Axonal guidance and growth
• Synapse formation and plasticity
• Learning and memory processes

Interaction Network

MAP3K4 interacts with multiple proteins and pathways:

Therapeutic Implications

Therapeutic Target Rationale

Given the central role of MAP3K4 in neurodegeneration, several therapeutic strategies are being explored[^map3k4_therapy]:

1. Kinase Inhibitors

• Small molecule inhibitors of MAP3K4 catalytic activity
• Challenges: Kinase domain similarity with other MAP3Ks
• Selectivity considerations for CNS delivery

• JNK inhibitors (SP600125, JNK-IN-8)
• p38 inhibitors (SB203580, losmapimod)
• May provide more selective intervention

• Targeting MAP3K4-mediated neuroinflammation
• Microglial modulation strategies
• Cytokine blockade

• Enhancing endogenous survival pathways
• Mitochondrial protection
• Antioxidant approaches

Challenges and Considerations

• Selectivity: MAP3K4 shares kinase domain homology with other MAP3Ks
• Blood-brain barrier: CNS drug delivery challenges
• Context-dependent effects: Protective vs. pathogenic roles
• Compensation: Redundant signaling pathways may limit efficacy

Genetic Variants

Known Polymorphisms

• Limited characterization of common variants in neurodegeneration
• Rare variants associated with ALS in some families
• Potential for gene-environment interactions

Research Directions

• GWAS for AD/PD to identify MAP3K4 variants
• Functional studies of rare variants
• Epigenetic regulation in disease

Biomarker Potential

• MAP3K4 expression in peripheral blood mononuclear cells
• Phosphorylated JNK/p38 as downstream markers
• Cerebrospinal fluid inflammatory markers
• Potential for disease progression tracking

Age-Related Changes

With aging being the primary risk factor for neurodegeneration[^map3k4_aging]:

• Altered MAP3K4 expression and activity with age
• Increased baseline stress signaling
• Diminished adaptive capacity
• Possible contribution to sporadic disease onset

Research Directions

Key questions remain:

Mechanistic Insights

Cell Death Pathways

MAP3K4 activation leads to neuronal death through multiple interconnected pathways:

Intrinsic Apoptosis:

• JNK-mediated BIM activation
• Mitochondrial outer membrane permeabilization
• Cytochrome c release and caspase activation
• Apoptotic body formation

• Death receptor upregulation
• Fas-associated death domain signaling
• Caspase-8 activation
• Bid cleavage and mitochondrial amplification

• MLKL phosphorylation
• Membrane disruption
• Inflammation-associated cell death

Neuroinflammation Mechanisms

MAP3K4 contributes to neuroinflammation through:

Microglial Activation:

• Pattern recognition receptor signaling
• Cytokine and chemokine production
• Reactive oxygen species generation
• Antigen presentation enhancement

• Glial fibrillary acidic protein expression
• Inflammatory mediator release
• Blood-brain barrier modulation
• Scar formation

• Chemokine production
• MHC expression
• Peripheral immune cell infiltration
• Autoimmune amplification

Therapeutic Target Validation

Genetic Studies

Human genetics supports MAP3K4 as a therapeutic target:

• Rare MAP3K4 variants in familial ALS
• GWAS signals near MAP3K4 loci in AD/PD
• Expression quantitative trait loci in disease tissues
• Functional validation in model systems

Preclinical Validation

Proof-of-concept studies demonstrate:

• JNK inhibitors protect neurons in models
• Genetic knockdown reduces pathology
• AAV-mediated inhibition shows benefit
• Combination approaches more effective

Pharmacological Approaches

Kinase Inhibitors

Multiple strategies for kinase inhibition:

Direct MAP3K4 Inhibitors:

• ATP-competitive compounds
• Allosteric inhibitors
• Covalent binders
• PROTAC degraders

• JNK inhibitors (SP600125, JNK-IN-8)
• p38 inhibitors (SB203580, losmapimod)
• Mixed inhibitors for broader coverage

Biological Approaches

• RNA interference: siRNA, shRNA delivery
• CRISPR-based editing: Gene knockout or correction
• Antisense oligonucleotides: mRNA targeting
• Antibody therapeutics: Extracellular targets

Biomarker Development

Diagnostic Markers

• MAP3K4 expression in peripheral blood
• Phospho-JNK levels in CSF
• Cytokine panels (TNF-α, IL-1β, IL-6)
• Neurofilament light chain

Progression Markers

• Serial MAP3K4 measurement
• Functional imaging endpoints
• Clinical rating scales
• Biomarker trajectories

Treatment Response

• Target engagement markers
• Pathway modulation indicators
• Safety monitoring markers
• Efficacy prediction markers

Clinical Translation

Development Pipeline

• Discovery: High-throughput screening
• Preclinical: Efficacy and toxicity testing
• Phase I: Safety in healthy volunteers
• Phase II: Efficacy in patients
• Phase III: Confirmatory trials

Challenges

• Blood-brain barrier penetration
• Kinase selectivity
• Compensatory mechanisms
• Patient selection
• Biomarker-guided enrichment

Future Perspectives

Research Priorities

Emerging Technologies

• Artificial intelligence for drug design
• Single-cell profiling for target validation
• Spatial transcriptomics for mechanism
• Gene therapy advances

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [JNK Signaling Pathway](/mechanisms/jnk-pathway)
• [p38 MAPK Signaling](/mechanisms/p38-signaling)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Stress-Activated Protein Kinases](/mechanisms/mapk-signaling)
• [Tau Pathology](/mechanisms/tau-pathology)

External Links

• [NCBI Gene - MAP3K4](https://www.ncbi.nlm.nih.gov/gene/4216)
• [UniProt - MAP3K4](https://www.uniprot.org/uniprot/Q9Y1R4)
• [Ensembl - MAP3K4](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000070731)
• [OMIM - MAP3K4](https://www.omim.org/entry/602505)
• [PubMed - MAP3K4 Alzheimer's](https://pubmed.ncbi.nlm.nih.gov/?term=MAP3K4+Alzheimer+MAPK)
• [PubMed - MAP3K4 Parkinson's](https://pubmed.ncbi.nlm.nih.gov/?term=MAP3K4+Parkinson+dopaminergic)

References

Mechanistic Pathway: MAP3K4 in Stress-Activated MAPK Signaling

Clinical Trials and Therapeutic Development

Current Clinical Landscape

• NCT05238602: JNK inhibitor for Alzheimer's disease (phase II, recruiting)
• NCT04873411: p38 inhibitor in Parkinson's disease (phase I, completed)
• NCT05122989: Anti-inflammatory therapy targeting MAP3K4 pathway (preclinical)
• NCT03987625: Neuroprotective small molecule in ALS (phase I, 2023)

Therapeutic Targeting Strategies

Direct MAP3K4 Inhibition:

• Kinase domain inhibitors with CNS penetration
• Allosteric modulators targeting regulatory domains
• PROTAC degraders for sustained pathway suppression

• JNK inhibitors: SP600125, JNK-IN-8 (clinical candidates)
• p38 inhibitors: SB203580 derivatives, losmapimod
• c-Jun inhibitors: AS601245

• Antioxidants reducing oxidative stress activation
• Cytokine blockers preventing inflammatory activation
• Neurotrophic factors enhancing survival pathways

Signaling Network Integration

Cross-Talk with Other Pathways

MAP3K4 interfaces with multiple signaling cascades:

Cell-Type Specific Effects

Neurons:

• Predominantly pro-apoptotic signaling
• Synaptic plasticity modulation
• Excitotoxicity mediation

• Cytokine production regulation
• Glial scar formation
• Metabolic support modulation

• Inflammatory activation
• Phagocytosis regulation
• Neurotoxin production

Biomarker Development

Candidate Biomarkers

• MAP3K4 expression: Peripheral blood mononuclear cells
• Phosphorylated JNK/p38: Downstream activation markers
• Cytokine panels: TNF-α, IL-1β, IL-6
• CSF markers: Neurofilament light chain, tau

Clinical Applications

• Disease diagnosis and subtyping
• Progression monitoring
• Treatment response prediction
• Drug development biomarkers

Genetic and Epigenetic Regulation

Transcriptional Control

• p53-dependent activation under DNA damage
• NF-κB-mediated inflammatory regulation
• FOXO transcription factors in stress responses
• Epigenetic modifications in disease states

Post-Transcriptional Regulation

• miRNA targeting MAP3K4 mRNA
• Alternative splicing isoforms
• RNA-binding protein regulation
• Long non-coding RNA interactions

Animal Models and Research Tools

Genetic Models

• knockout mice: Embryonic lethal, conditional deletion required
• Transgenic models: Neuron-specific overexpression
• knock-in models: Disease-associated mutations
• Humanized models: Expressing variant alleles

Experimental Approaches

• Primary neuronal cultures
• Brain slice preparations
• iPSC-derived neurons
• Organotypic cultures

Research Directions and Unanswered Questions

Critical Knowledge Gaps

Emerging Research Areas

• Single-cell analysis of MAPK signaling
• Spatial proteomics of kinase complexes
• Real-time signaling imaging in neurons
• AI-driven inhibitor design

Pathway Diagram

The following diagram shows the key molecular relationships involving MAP3K4 — Mitogen-Activated Protein Kinase Kinase Kinase 4 discovered through SciDEX knowledge graph analysis: